Cellular Therapy
From the Journals
CLL, GVHD may raise risk for skin cancer after allo-HCT
The retrospective analysis identifies previously unknown risk factor for skin cancer associated with allogeneic hematopoietic cell transplantation...
Conference Coverage
Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML
HOUSTON – The effect was most pronounced in those with high pFLT3 inhibition on plasma inhibitor activity assay.
Conference Coverage
ZUMA-1 update: Axi-cel responses persist at 2 years
HOUSTON – Median duration of response and overall survival have not yet been reached in the pivotal CAR T-cell therapy trial.
Conference Coverage
Dual-targeted CAR T shows ‘clinical signal’ in NHL
HOUSTON – Due to local manufacturing of the CAR T-cell therapy, most patients were able to receive fresh, rather than cryopreserved, product.
Conference Coverage
AlloBMT should be option for older adults with hematologic malignancies
HOUSTON – Allogeneic BMT should not be denied in older adults with hematologic malignancies based on age alone.
Conference Coverage
MRD negativity linked to survival in MM after auto-HCT
HOUSTON – MRD-negative status was prognostic for improved progression-free survival at all time points measured after transplant.
Conference Coverage
Anti-GM-CSF antibody reduced CAR T-cell toxicity
HOUSTON – An early study shows the potential of lenzilumab to reduce CAR T-cell toxicity.
Conference Coverage
Treosulfan may become standard in allo-HCT for AML/MDS
HOUSTON – A treosulfan-based myeloablative conditioning regimen was noninferior to the reduced intensity busulfan-based regimen in event-free...
Conference Coverage
Ultrasound method predicts liver complications in pediatric transplant
HOUSTON – Using shear wave elastography predicted disease at least 4 days before standard diagnostic criteria in most patients.
From the Journals
Haplo-HCT shows viability in DLBCL
Survival rates were similar for matched and unmatched donors.
Conference Coverage
PD-1 blockade plus CD19 CAR T boosts CAR T-cell persistence
SAN DIEGO – The combination appears to bolster CAR T-cell effects and persistence in children with relapsed B-ALL.